The Insight Partners is proud to announce its latest market report, “Gene Therapy Market: An In-Depth Analysis of the Gene Therapy Market.” This comprehensive report explores current trends, technological breakthroughs, regulatory developments, and key growth areas shaping the future of gene therapy.

Market Overview

The gene therapy market changes healthcare because it gives targeted treatments for genetic disorders, cancers, and rare diseases. This industry is experiencing strong upward momentum with the increase in clinical approvals along with the development of new gene-editing tools. The market is expected to progress to US$ 25.69 billion by 2031 from US$ 5.11 billion in 2023 at a CAGR of 14.3% during the forecast period 2023-2031.

Download Sample PDF Copy https://www.theinsightpartners.com/sample/TIPHE100001165/

Key Market Insights

Market Size and Growth

• 2023 Market Size: US$ 5.11 Billion

• 2031 Market Forecast: US$ 25.69 Billion

• CAGR (2023–2031): 14.3%

Key Growth Drivers

• Sustained progress in CRISPR and other gene-editing technologies

• Growing pipeline of gene therapy candidates in oncology and neurology

• Rising approvals of in vivo and ex vivo treatments

• Strong regulatory support for orphan and rare diseases

Market Segmentation

• By Vectors: Non-Viral Vectors and Viral Vectors

• By Indication: Neurological Diseases, Cancer, Duchenne Muscular Dystrophy, Hepatological Diseases, Other Indications.

• By Delivery Mode: In Vivo, Ex Vivo

Emerging Trends

• Transition towards non-viral delivery platforms to enhance scalability and safety

• Increasing emphasis on personalized gene therapies and targeted delivery

• Extension in neurology indications, such as Duchenne muscular dystrophy and SMA

• Fast-tracked approval routes by FDA and EMA for gene therapy products

Growth Opportunities

• Unpenetrated markets in Asia-Pacific and Latin America

• New applications outside of rare diseases—like cardiovascular and autoimmune disease

• Strategic partnerships and licensing between biotech and pharma companies

• Decentralized production and new delivery technologies

Conclusion

The Gene Therapy Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023–2031 report is a critical source of information for stakeholders interested in grasping the drivers influencing this high-growth industry. With robust R&D momentum and rising clinical success rates, the market is on the cusp of revolutionary growth.

FAQ

Q1. What is the size and growth rate of the gene therapy market currently?

The size of the gene therapy market was US$ 5.11 billion in 2023 and is expected to reach US$ 25.69 billion by 2031, expanding at a CAGR of 14.3%.

Q2. Why is this market growing?

Major growth drivers are technology advancements in gene editing, regulatory approvals, higher funding, and the need for therapies in rare diseases and cancers.

Q3. Which segments will dominate the market?

The oncology and neurology segments will dominate, with viral vectors like AAV being the leader in delivery methods. In vivo treatments are the most common method.

Q4. What are the challenges for the gene therapy industry?

Significant hurdles are high development and production expenses, delivery complexity, possible safety threats, and limited access in low-income areas.

Q5. Which are the regions with the quickest growth in gene therapy adoption?

North America dominates market share, but Asia-Pacific will see the quickest growth as a result of growing investment, clinical trials, and regulatory liberalization.

Q6. Who are the key players in the gene therapy marketplace?

Leading companies include Novartis AG, Sarepta Therapeutics, Spark Therapeutics, Bluebird Bio, CRISPR Therapeutics, and BioMarin Pharmaceutical.